Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study

BACKGROUND: Apatinib, a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), has exhibited modest antitumor efficacy in hepatocellular carcinoma (HCC). We aimed to evaluate the effectiveness and tolerability of apatinib versus sorafenib in patients with advanced HCC. METHO...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Transl Med
Asıl Yazarlar: He, Wei, Liao, Leen, Hu, Dandan, Li, Binkui, Wang, Chenwei, Qiu, Jiliang, Liao, Yadi, Liu, Wenwu, Yang, Zhiwen, Zhang, Yuanping, Yuan, Yichuan, Li, Kai, Yuan, Yunfei, Zheng, Yun
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475472/
https://ncbi.nlm.nih.gov/pubmed/32953800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-5298
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller